Safety of Low-Dose Tanezumab in the Treatment of Hip or Knee Osteoarthritis: A Systemic Review and Meta-analysis of Randomized Phase III Clinical Trials.
Sign Up to like & getrecommendations! Published in 2020 at "Pain medicine"
DOI: 10.1093/pm/pnaa260
Abstract: OBJECTIVES To evaluate the safety of low-dose tanezumab in the treatment of knee or hip osteoarthritis (OA). METHODS Databases were searched up to September 2019 for phase III randomized controlled trials (RCTs). Eleven phase III… read more here.
Keywords: safety low; low dose; treatment; tanezumab ... See more keywords
Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2017 at "Pain Medicine"
DOI: 10.1093/pm/pnw262
Abstract: Objectives. To evaluate the efficacy and safety of tanezumab for management of osteoarthritis (OA) knee and hip pain. Methods. Articles about management of OA knee and hip pains by tanezumab were systematically searched in PubMed, EBSCO, EMBASE,… read more here.
Keywords: knee hip; safety tanezumab; tanezumab;
O06 Improvements in pain, function and health status with subcutaneous tanezumab compared with placebo in patients with OA: pooled analysis of two randomized controlled trials
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa110.005
Abstract: Osteoarthritis (OA) causes pain, disability and impaired quality of life. Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the management of OA pain. Two randomised, placebo-controlled studies with a primary aim… read more here.
Keywords: week; tanezumab; group; study ... See more keywords
AB0859 IMPROVEMENTS IN PHYSICAL FUNCTION IN PATIENTS WITH OSTEOARTHRITIS RECEIVING SUBCUTANEOUS TANEZUMAB IN 3 RANDOMIZED CONTROLLED TRIALS
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.953
Abstract: Background: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the treatment of the signs and symptoms of osteoarthritis (OA). Objectives: To assess the improvement in physical function following treatment with subcutaneous… read more here.
Keywords: tanezumab; physical function; study; group ... See more keywords